Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

26.10
+0.12000.46%
Post-market: 26.100.00000.00%19:30 EDT
Volume:1.18M
Turnover:31.06M
Market Cap:4.87B
PE:-7.79
High:26.87
Open:26.22
Low:26.02
Close:25.98
52wk High:27.31
52wk Low:11.92
Shares:186.58M
Float Shares:186.00M
Volume Ratio:0.71
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:6.94
PE(LYR):-7.51

Loading ...

Dyne to present primate data showing FORCE platform crosses blood-brain barrier

Reuters
·
Apr 28

Dyne director Dirk Kersten reports DYN share sale worth $219,364

Reuters
·
Apr 24

Dyne Therapeutics grants inducement awards to 18 new employees under Nasdaq rule

Reuters
·
Apr 24

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 24

Dyne Therapeutics director Dirk Kersten disposes of USD 6.8 million common shares

Reuters
·
Apr 22

Dyne director Dirk Kersten disposes of $2,021,419 Dyne Therapeutics shares

Reuters
·
Apr 18

Dyne Therapeutics Advances Pivotal DYNE-101 Trial in Myotonic Dystrophy Type 1

TIPRANKS
·
Apr 17

Dyne Therapeutics announces annual shareholder meeting agenda

Reuters
·
Apr 10

Dyne director Brian S. Posner acquires Dyne Therapeutics shares worth $0.03 million

Reuters
·
Apr 02

Dyne to present DELIVER, ACHIEVE trial data at AMCP as it readies US DMD launch

Reuters
·
Apr 01

J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
Mar 16

Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case

Simply Wall St.
·
Mar 15

Top Dyne Therapeutics Insider Quietly Boosts Stake in Bold New Move

TIPRANKS
·
Mar 14

Dyne Therapeutics Director Dirk Kersten Disposes of Common Shares

Reuters
·
Mar 14

Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data

Simply Wall St.
·
Mar 13

Dyne Therapeutics Director Dirk Kersten Disposes of Common Shares

Reuters
·
Mar 12

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO) and Dyne Therapeutics (DYN)

TIPRANKS
·
Mar 10

Dyne Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 10

Dyne Therapeutics (DYN) Is Down 8.0% After Advancing Key Neuromuscular Trials Has The Bull Case Changed?

Simply Wall St.
·
Mar 10

Dyne Therapeutics Rises on Positive Data for Duchenne Muscular Dystrophy Treatment

Dow Jones
·
Mar 10